Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Rhea-AI Summary

Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced a conference call and webcast scheduled for August 8, 2024, at 8:30 a.m. ET. The event will cover the company's second quarter 2024 financial results and provide a business update. Ocugen plans to release a pre-market earnings announcement on the same day.

Interested parties can join the call using the following details:

• U.S. callers: (800) 715-9871
• International callers: (646) 307-1963
• Conference ID: 7453742

A webcast will be available on the events section of Ocugen's investor site. A replay of the call and archived webcast will be accessible for approximately 45 days after the event.

Positive

• Ocugen is proactively communicating with investors by hosting a conference call and webcast
• The company will provide Q2 2024 financial results and a business update

Negative

• None.

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 8, 2024.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 7453742
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

When will Ocugen (OCGN) release its Q2 2024 financial results?

Ocugen (OCGN) will release its Q2 2024 financial results in a pre-market earnings announcement on August 8, 2024.

What time is Ocugen's (OCGN) Q2 2024 earnings call scheduled for?

Ocugen's (OCGN) Q2 2024 earnings call is scheduled for Thursday, August 8, 2024, at 8:30 a.m. ET.

How can investors access Ocugen's (OCGN) Q2 2024 earnings call?

Investors can access Ocugen's (OCGN) Q2 2024 earnings call by dialing (800) 715-9871 for U.S. callers or (646) 307-1963 for international callers, using the Conference ID: 7453742. A webcast will also be available on the events section of Ocugen's investor site.

How long will the replay of Ocugen's (OCGN) Q2 2024 earnings call be available?

The replay of Ocugen's (OCGN) Q2 2024 earnings call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.